Skip to main content

Oncology Precision Medicine Market Expected to reach US$ 148.66 Billion with 11.21% CAGR Forecast to 2030

 Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare. The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of healthcare, and public investment led to the evolution of the personalization of disease-based therapies.

This evolution within precision medicine will profoundly impact the biopharmaceutical industry, and multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change.

The global oncology precision medicine market was valued at $46.90 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.21% and reach a value of $148.66 billion in 2030.

The existing oncology precision medicine market is favored by multiple factors, which include rising cancer incidences and death rates, several government initiatives, coupled up with the general population’s growing awareness pertaining to molecular level diagnosis and treatment. Additionally, the increasing number of advancements in molecular diagnostics, increasing FDA approvals for such precision medicine-based oncology drugs, improving focus on research and development activities by key healthcare companies are also leading toward market expansion.

Within the research report, the market is segmented on the basis of application (breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, other applications), ecosystem type (applied sciences, precision diagnostics, digital health and information technology, precision therapeutics), and region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

The oncology precision medicine market witnessed 78 collaborations and partnerships, four funding and investments, 45 product launches and enhancements, 22 regulatory and legal activities, 17 mergers and acquisitions, and six business expansions.

Major players within the oncology precision medicine market are Abbott Laboratories, Agilent Technologies, Inc., Almac Group Ltd., ANGLE plc, Asuragen Inc., AstraZeneca PLC, Bristol Myers Squibb, bioMérieux SA., BGI Group, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc, Konica Minolta, Inc., Laboratory Corporation of America Holdings, MDx Health, Inc., Myriad Genetics, Inc., Novartis AG, Opko Health,Inc., Pacific Biosciences of California, Inc.,Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics.

Key Questions Answered in this Report:

•    What are the most common causes of cancer deaths globally?
•    What are the emerging technologies that can take over the current technologies for molecular diagnosis within the oncology precision medicine market?
•    What is the patent expiry scenario of the key companion diagnostics-based drugs within the market?
•    How are the key market players performing research investments in the respective market?
•    Who are the upcoming start-ups within the oncology precision medicine market and their funding scenario?
•    What are the key development strategies implemented by the key players to stand out in this market?
•    How have the strategic collaborations among the key players and academia, providing a push to product development within the oncology precision medicine market? 
•    What are the regulations pertaining to the precision medicine in oncology among different regions and their impact over the respective market?
•    What are the initiatives implemented by different government bodies regulating the development and commercialization of oncology precision medicine products and associated platforms?
•    How has COVID-19 impacted the oncology precision medicine market?
•    How will the urgency of the pandemic influence the global oncology precision medicine market?
•    What are the leading companies dominating the global oncology precision medicine market?
•    What is the reimbursement scenario of the products offered in the global oncology precision medicine market?
•    Based on the application area, which global oncology precision medicine market application area is anticipated to witness a massive rise in demand in the forecast period?
•    How is each segment of the global oncology precision medicine market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2030?
•    How is the global oncology precision medicine industry anticipated to evolve during the forecast period 2020-2030?
•    What are the leading trends and consumer preferences witnessed in the global oncology precision medicine market?

Request a Sample- https://bisresearch.com/requestsample?id=1026&type=download

Labels:

Comments

Post a Comment

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more

Digital PCR Market size,Share, Leading Players, Growth, Development and Demand Forecast to 2032

  Increasing investments in R&D for d-PCR molecular diagnostics is one of the major opportunities in the global digital PCR market. Several biotechnology and life sciences companies are working collaboratively on diagnostic test development and using d-PCR as a therapeutic means for applications in several disease indications to enable efficient diagnosis, treatment selection, and treatment monitoring. The global  digital PCR market   is projected to reach $2,847.8 million by 2032 from $441.2 million in 2021, at a CAGR of 18.73% during the forecast period 2022–2032. The growth in the global digital PCR market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases globally, the rising awareness of d-PCR-based diagnostic testing, and the significant number of funding for executing research and development. Impact of COVID-19 The current global digital PCR market comprises kits and assays, system, and reagents and consuma...
Post a Comment
Read more

Radiation Dose Management Market Likely To Increase Size, Shares, And Demand Forecast 2022-2032

  Radiation dose is the amount of radiation absorbed by a patient during a diagnostic imaging procedure. A large dose of radiation can cause tissue damage and increase the risk of developing cancer in later stages of life.The development of on-cloud dose management solutions and the growing initiatives on radiation dose management for pediatric procedures are some of the major opportunities in the global radiation dose management market. Furthermore, some of the key trends going on in the market include the increasing development of imaging modalities with technologies that lower radiation dose, partnerships and strategic business alliances dominating the market, and various collaborations among market players. The global  radiation dose management market   was valued at $212.8 million in 2021 and is anticipated to reach $586.7 million by 2032, witnessing a CAGR of 10.30% during the forecast period 2022–2032. The growth in the global radiation dose management market is ex...
Post a Comment
Read more